Pyxis Oncology, Inc. (NASDAQ: PYXS) has commenced a registered public offering to raise capital for advancing its lead clinical program, micvotabart pelidotin (MICVO). The company aims to use net proceeds to support key milestones in its Phase 3 trial for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Specific financial terms of the offering remain undisclosed as the transaction is subject to market conditions.

Offering structure and terms

The offering consists of shares of common stock or pre-funded warrants, each accompanied by a common warrant to purchase one share of common stock. The pre-funded warrants serve as an alternative to common stock for certain investors. All securities are being sold directly by Pyxis Oncology.

The common warrants attached to the shares have specific exercisability conditions. They become exercisable only after stockholders approve an amendment to the company’s certificate of incorporation to increase authorized shares. This amendment must also be effective. The warrants expire on the earlier of:

1. The fifth anniversary of the Charter Amendment Effective Date.
2. The 30th calendar day following the later of the Charter Amendment Effective Date and the public disclosure of overall survival data from the ongoing Phase 1 monotherapy study of MICVO.

The overall survival data is expected to be released in the first half of 2027.

Use of proceeds and clinical focus

Pyxis Oncology intends to allocate the net proceeds from this offering toward advancing MICVO through critical clinical milestones. A primary focus is the Headliner™ trial, a planned Phase 3 study in second-line and beyond (2L+) R/M HNSCC. Remaining funds will cover working capital and general corporate purposes.

MICVO is a first-in-concept antibody-drug conjugate targeting extradomain-B of fibronectin (EDB+FN). This target is selectively overexpressed in tumor microenvironments but largely absent in normal adult tissues. The drug utilizes a three-pronged mechanism of action: direct cancer cell killing, bystander effect, and immunogenic cell death.

Underwriters and regulatory status

Leerink Partners, Guggenheim Securities, and Wells Fargo Securities are acting as joint bookrunning managers for the proposed offering. The transaction is subject to market conditions and other factors, with no assurance regarding completion, size, or final terms.

The securities are offered pursuant to a registration statement on Form S-3 (File No. 333-291801), previously filed with and declared effective by the Securities and Exchange Commission (SEC). The offering will be conducted via a prospectus supplement and accompanying prospectus part of this registration statement.

What the numbers show

The structure of the offering reveals a strategic alignment between financing and clinical timelines. By tying warrant expiration to the release of overall survival data in the first half of 2027, Pyxis effectively caps the dilution window tied to its most significant near-term catalyst. This suggests the company prioritizes funding through this pivotal data readout while managing long-term equity overhang by limiting the lifespan of the attached warrants.

Pyxis Oncology, Inc. (NASDAQ: PYXS) announced it will host a live webcast on September 9, 2026, at 7:30 am Eastern Time to present updated clinical data from its ongoing Phase 1 monotherapy study. The study evaluates micvotabart pelidotin (MICVO) in patients with second-line and beyond (2L+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Clinical Presentation Details

The presentation will cover the scientific rationale for MICVO, a novel antibody-drug conjugate (ADC), and its implications within the evolving treatment landscape for R/M HNSCC. Key data points include detailed analyses of patients treated at 5.4 mg/kg intravenously once every three weeks, specifically those receiving a dose equivalent to or below a dose cap.

Updated efficacy and safety results from the expansion trial will be disclosed, alongside next steps in clinical development. The event features Alan L. Ho, M.D., Ph.D., Chief of Head and Neck Oncology Service at Memorial Sloan Kettering Cancer Center, along with Pyxis Oncology management.

Regulatory and Development Context

MICVO holds Fast Track Designation from the U.S. Food and Drug Administration for treating adult patients with R/M HNSCC whose disease progressed following platinum-based chemotherapy and anti-PD-(L)1 therapy. The drug targets extradomain-B of fibronectin (EDB+FN), a structural component of the tumor extracellular matrix selectively overexpressed in solid tumors.

Pyxis Oncology is also evaluating MICVO in combination with Merck’s KEYTRUDA (pembrolizumab) in a Phase 1/2 study for R/M HNSCC and other solid tumors. An archived webcast will be available on the company’s investor relations website following the live event.